AR-701 (COVID-19 mAb) Monoclonal Antibody Description
Aridis Pharmaceuticals's AR-701 combines two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody-secreting B-cells of convalescent SARS-CoV-2 infected (COVID-19) patients.
AR-701 consists of AR-703 and AR-720 mAbs; each neutralizes coronaviruses using distinct mechanisms of action, namely inhibition of viral fusion and entry into human cells (AR-703) and blockage of viral binding to the human 'ACE2' receptor (AR-720).
AR-701 comprises multiple fully human IgG1s monoclonal antibodies directed at conserved regions of the SARs-CoV-2 envelope proteins. AR-701 mAbs are designed to maintain broad coverage of SARs-CoV-2, including recently reported variants of SARS-CoV-2 such as the D614G variant, possible future variants of SARS-CoV-2. Furthermore, AR-701 mAbs have been engineered for a prolonged duration of protection well beyond that afforded by typical mAbs. AR-701 is designed to block the binding and propagation of infection by SARS-CoV-2 of human lung cells.
The Company's proprietary technology platforms, ⅄PEX and MabIgX®, can rapidly identify human-derived monoclonal antibodies for various infectious diseases and apply them in a brand-new way as therapeutic agents that optimally neutralize invading pathogens.
Aridis Pharmaceuticals Inc. (Nasdaq: ARDS) is located at 983 University Avenue Suite B, Los Gatos, CA 95032. The Company is advancing multiple clinical-stage mAbs targeting bacteria that cause life-threatening infections such as ventilator-associated pneumonia and hospital acquired pneumonia, in addition to antiviral mAbs.
AR-701 (COVID-19 mAb) Monoclonal Antibody Indication
The antibody cocktail AR-701 has been tested in vitro neutralization studies using live coronaviruses. AR-701 achieved broad, potent neutralization against all SARS-CoV-2 variants tested, as well as SARS, MERS, and the seasonal 'common cold' betacoronaviruses.
AR-701 (COVID-19 mAb) Monoclonal Antibody History
AR-701 was identified by screening the blood of COVID-19 convalescent of patients in the U.S. and EU using Aridis' ⅄PEXTM platform technology.
Aridis Pharmaceuticals Inc. Financial News (Nasdaq: ARDS)
December 21, 2021 - The Company announced Vu Truong, Ph.D., Chief Executive Officer, was interviewed on Varney & Co., hosted by Stuart Varney, on Fox Business.
November 10, 2021 - Fiscal 2021 Third Quarter Results: Cash: Total cash and cash equivalents as of September 30, 2021, were approximately $18.2 million; Revenues: Grant Revenue increased to $0.4 million for the three months ended September 30, 2021, from zero for the three months ended September 30, 2020, due to achievement of the first of four Phase 2a clinical trial milestones related to the evaluating AR-501 for the treatment of Cystic Fibrosis under the award from the CF Foundation in the three months ended September 30, 2021.
August 2, 2021 - Aridis Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common stock, at an effective purchase price of $5.053 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Aridis Pharmaceuticals, Inc. 4Q'21 Investor Presentation
AR-701 (COVID-19 mAb) Monoclonal Antibody News
December 21, 2021 - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced that its fully human monoclonal antibody (mAb) cocktail AR-701 is broadly reactive against the Omicron and other COVID-19 (SARS-CoV-2) variants, SARS-1, MERS, and seasonal ('common cold') human coronaviruses.
July 26, 2021 - Aridis Pharmaceuticals, Inc. announced that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium has studied to date.
July 12, 2021 - Aridis Pharmaceuticals, Inc. announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC Variants of Interest and Variants of Concern lists.
AR-701 (COVID-19 mAb) Monoclonal Antibody Clinical Trials
The Company published various disclosures and information.